source
- Compass Therapeutics unveils key secondary endpoint results from pivotal biliary tract cancer trialA year after it reported a Phase 2/3 success, Compass Therapeutics on Monday revealed further results for its closely watched bispecific antibody in second-line biliary tract cancer. While the inve…Endpoints · 3mo ago↗ source
- Intellia's in vivo CRISPR therapy first to succeed in Phase 3An experimental treatment that uses CRISPR to edit genes directly inside the body has just succeeded in a Phase 3 trial — a first for the technology — putting it on track for a potential FDA approv…Endpoints · 3mo ago↗ source
- STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trialWith good results from Intellia, the CRISPR field faces the question: How attractive will the one-and-done approach be to patients and doctors?